Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026

Bulletin Express

04/14

Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).

According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.

Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.

The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.

Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1188331019"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188331019\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188331019?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 20:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188331019","market":"us","top_or_hot":-1,"title":"Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026","media":"Bulletin Express","content":"<p>Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).</p>\n<p>According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.</p>\n<p>Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.</p>\n<p>The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.</p>\n<p>Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Genscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGenscript: Legend Biotech Posts US$597.00 Million CARVYKTI® Net Sales for Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-04-14 20:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).</p>\n<p>According to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.</p>\n<p>Legend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.</p>\n<p>The announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.</p>\n<p>Genscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01548","symbol_name":"金斯瑞生物科技","start_time":0,"source_url":"","article_id":"1188331019","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188331019","pubTimestamp":1776168205,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI®...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01548":"金斯瑞生物科技"},"translate_title":"金斯瑞：传奇生物斥资5.97亿美元收购CARVYKTI®2026年第一季度净销售额","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01548":1},"content_text":"Genscript Biotech Corporation (GENSCRIPT BIO, 01548) announced that its associate Legend Biotech Corporation has reported preliminary net trade sales of approximately US$597.00 million for CARVYKTI® during the quarter ended 31 March 2026. The figure was disclosed in Legend’s Form 6-K filed with the U.S. Securities and Exchange Commission on 14 April 2026 (New York time).\nAccording to the filing, the sales data were provided to Legend by collaboration partner Janssen Biotech, Inc. under their December 2017 Collaboration and License Agreement. Genscript and Legend have not independently verified the numbers.\nLegend Biotech, listed on the Nasdaq Global Select Market via American Depositary Shares, had previously released preliminary CARVYKTI® sales data for the quarter ended 31 December 2025 on 21 January 2026.\nThe announcement reiterates forward-looking statement cautions, citing potential risks such as clinical outcomes, regulatory actions, intellectual property challenges, and competitive pressures, as outlined in Legend’s Form 20-F filed on 10 March 2026.\nGenscript’s board advises shareholders and potential investors to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}